X
API Suppliers
US DMFs Filed
CEP/COS Certifications
JDMFs Filed
Other Certificates
Other Suppliers
0
USA (Orange Book)
Europe
Canada
Australia
0
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
0
Details:
Triamcinolone Hexacetonide is a longest-acting corticosteroid for intra articular injection. The companies have agreed to a small upfront fee along with milestone payments at the time of FDA approval, at commercial product launch, and upon certain sales milestones.
Lead Product(s): Triamcinolone Acetonide
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Medexus Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement December 18, 2020
Details:
USFDA approved generic version of Triamcinolone Acetonide, a corticosteroid hormone receptor agonist ointment, which is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid responsive dermatoses.
Lead Product(s): Triamcinolone Acetonide
Therapeutic Area: Dermatology Product Name: Triamcinolone Acetonide-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 02, 2020
Details:
USFDA approved generic version of Triamcinolone Acetonide Ointment which is a class of medications called corticosteroids. It is used to treat the itching, redness, dryness, crusting, scaling, inflammation, and discomfort of various skin conditions, including psoriasis.
Lead Product(s): Triamcinolone Acetonide
Therapeutic Area: Dermatology Product Name: Triamcinolone Acetonide-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 24, 2020
Details:
Harrow diversified its portfolio of branded pharmaceutical products by acquiring 5 ophthalmic products, Ilevro, Nevanac, Vigamox, Maxidex, and Triesence. Triamcinolone acetonide is a synthetic corticosteroid indicated for sympathetic ophthalmia, temporal arteritis and uveitis.
Lead Product(s): Triamcinolone Acetonide
Therapeutic Area: Rare Diseases and Disorders Product Name: Triesence
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Harrow
Deal Size: $130.0 million Upfront Cash: Undisclosed
Deal Type: Acquisition November 29, 2023
Details:
KOURZEQ (triamcinolone acetonide dental paste USP, 0.1%) is an FDA-approved prescription medicine that is used to treat oral lesions, including canker sores in adults.
Lead Product(s): Triamcinolone Acetonide
Therapeutic Area: Immunology Product Name: Kourzeq
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 14, 2023
Details:
Xipere (triamcinolone acetonide injectable suspension) for suprachoroidal use is a proprietary suspension of the corticosteroid triamcinolone acetonide for administration to the suprachoroidal space for the treatment of macular edema associated with uveitis.
Lead Product(s): Triamcinolone Acetonide
Therapeutic Area: Ophthalmology Product Name: Xipere
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 04, 2023
Details:
Arcatus is a proprietary suspension of the corticosteroid triamcinolone acetonide for administration to the suprachoroidal space for the treatment of macular edema associated with uveitis and is referred as Xipere, approved in United States.
Lead Product(s): Triamcinolone Acetonide
Therapeutic Area: Ophthalmology Product Name: Arcatus
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Clearside Biomedical
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 10, 2023
Details:
Results with Xipere (triamcinolone acetonide) showed statistically significant reduction in tumor growth rate compared to each patient’s documented growth rate at study entry, and an 88.9% tumor control rate.
Lead Product(s): Triamcinolone Acetonide
Therapeutic Area: Ophthalmology Product Name: Xipere
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Bausch & Lomb Incorporated
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 04, 2022
Details:
XIPERE® is a triamcinolone acetonide injectable suspension for suprachoroidal use for the treatment of macular edema associated with uveitis, a form of eye inflammation.
Lead Product(s): Triamcinolone Acetonide
Therapeutic Area: Ophthalmology Product Name: Xipere
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 06, 2022
Details:
XIPERE (triamcinolone acetonide injectable suspension) for suprachoroidal use, formerly known as CLS-TA, is a proprietary suspension of corticosteroid triamcinolone acetonide for administration to suprachoroidal space for treatment of macular edema associated with uveitis.
Lead Product(s): Triamcinolone Acetonide
Therapeutic Area: Ophthalmology Product Name: Xipere
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 05, 2022
Details:
The commercialization of XIPERE® is an exciting step forward for the treatment of macular edema associated with uveitis, and also for increasing education and recognition of the suprachroidal space as a highly effective administration route for back-of-the-eye therapies.
Lead Product(s): Triamcinolone Acetonide
Therapeutic Area: Ophthalmology Product Name: Xipere
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Clearside Biomedical
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 28, 2022
Details:
The approved ANDA is therapeutically equivalent to the reference-listed drug product Nystatin and Triamcinolone Acetonide ointment, of strength 100,000 units/gram, used for the treatment of cutaneous candidiasis.
Lead Product(s): Nystatin,Triamcinolone Acetonide
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Aleor Dermaceuticals
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 08, 2022
Details:
Recent FDA approval of XIPERE™, first product approved for injection into the suprachoroidal space, and the first therapy approved for patients suffering from macular edema associated with uveitis.
Lead Product(s): Triamcinolone Acetonide
Therapeutic Area: Ophthalmology Product Name: Xipere
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 16, 2021
Details:
XIPERE™ (triamcinolone acetonide injectable suspension) for suprachoroidal use is a corticosteroid indicated for the treatment of macular edema associated with uveitis.
Lead Product(s): Triamcinolone Acetonide
Therapeutic Area: Ophthalmology Product Name: Xipere
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 25, 2021
Details:
This acquisition is a major milestone to build a robust offering of novel, non-opioid treatments to improve patient care along the neural pain pathway while simultaneously providing a complementary commercial asset in ZILRETTA for the treatment of OA knee pain.
Lead Product(s): Triamcinolone Acetonide
Therapeutic Area: Neurology Product Name: Zilretta
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Pacira BioSciences
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition October 11, 2021
Details:
XIPERE, referred to as ARVN001 by Arctic Vision, is a proprietary suspension of the corticosteroid triamcinolone acetonide formulated for administration to the suprachoroidal space (SCS®) using Clearside’s patented SCS Microinjector®.
Lead Product(s): Triamcinolone Acetonide
Therapeutic Area: Ophthalmology Product Name: Xipere
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Arctic Vision
Deal Size: Undisclosed Upfront Cash: $3.0 million
Deal Type: Licensing Agreement September 09, 2021
Details:
Under the terms of the agreement, Harrow Health will have marketing rights for the U.S. and Canada, while Wakamoto Pharmaceuticals will retain MAQ-100 marketing rights in other countries. Wakamoto will supply Harrow with MAQ-100.
Lead Product(s): Triamcinolone Acetonide
Therapeutic Area: Ophthalmology Product Name: MaQaid
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Harrow Health
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition August 18, 2021
Details:
ARVN001 is a proprietary suspension of the corticosteroid triamcinolone acetonide formulated for administration to the suprachoroidal space (SCS®) through Clearside’s patented SCS Microinjector®.
Lead Product(s): Triamcinolone Acetonide
Therapeutic Area: Ophthalmology Product Name: Xipere
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Clearside Biomedical
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement August 15, 2021
Details:
The virtual presentations will feature several of the company's prominent products from its pharmaceutical, surgical and vision care portfolios, including analyses on the company's investigational drug XIPERE™ (triamcinolone acetonide suprachoroidal injectable suspension).
Lead Product(s): Triamcinolone Acetonide
Therapeutic Area: Ophthalmology Product Name: Xipere
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 29, 2021
Details:
The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Nystatin and Triamcinolone Acetonide Cream USP, 100,000 units/gram and 1 mg/gram, of Taro Pharmaceuticals U.S.
Lead Product(s): Nystatin,Triamcinolone Acetonide
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 01, 2021
Details:
Arctic Vision currently has three late-stage in-licensed products: ARVN001 for uveitic macular edema (UME), ARVN002 for pediatric progressive myopia and ARVN003 for presbyopia.
Lead Product(s): Triamcinolone Acetonide
Therapeutic Area: Ophthalmology Product Name: ARVN001
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Loyal Valley Capital
Deal Size: $100.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing March 10, 2021
Details:
Clearside also announced that data from the Company’s Phase 2 clinical trial in diabetic macular edema (DME) was published in Ophthalmology Retina. The trial evaluated the investigational drug XIPERE™ used with intravitreally administered aflibercept in patients with DME.
Lead Product(s): Triamcinolone Acetonide
Therapeutic Area: Ophthalmology Product Name: Xipere
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 23, 2020
Details:
Triamcinolone Hexacetonide Injectable Suspension 20 mg/mL (TH) has been approved for inclusion as a general benefit (open listing) on the List of Medications- Institutions administered by the Régie de l’assurance maladie du Québec (RAMQ), effective August 19, 2020.
Lead Product(s): Triamcinolone Acetonide
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 24, 2020
Details:
TH is the longest acting corticosteroid for intra-articular injection, often lasting twice as long as comparator products.
Lead Product(s): Triamcinolone Acetonide
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 09, 2020
Details:
Under the amended deal, Bausch + Lomb has now been granted exclusive options for the right to commercialize and develop XIPERE in Europe and the U.K, Australia, New Zealand, South America and Mexico.
Lead Product(s): Triamcinolone Acetonide
Therapeutic Area: Ophthalmology Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Bausch + Lomb
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement April 28, 2020
Details:
The data demonstrated that patients with noninfectious uveitis in the XIPERE study arm experienced clinically significant improvement in vision relative to the control arm.
Lead Product(s): Triamcinolone Acetonide
Therapeutic Area: Ophthalmology Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 28, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
Ethypharm is an international Pharma company with European roots manufacturing and commercializing essential drugs all over the word. 
